Enterprise Value
-2.348M
Cash
8.677M
Avg Qtr Burn
-2.413M
Short % of Float
0.69%
Insider Ownership
16.23%
Institutional Own.
6.53%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PCS12852 Details Opioid induced constipation, Post-op GI Dysfunction | Phase 2a Update | |
NGC-Cap (PCS6422 w/ capecitabine) Details Solid tumor/s, Colorectal cancer , Cancer, Metastatic breast cancer | Phase 1b Data readout | |
PCS499 Details Ulcerative Necrobiosis Lipoidica | Failed Discontinued |